HOUSTONIntrogen Therapeutics, Inc. has published data from its phase II
study combining Advexin, an adenoviral vector containing the p53
tumor-suppressor gene, with radiation therapy in patients with nonmetastatic
non-small-cell lung cancer (NSCLC) (Clinical Cancer Research, January
2003). The patients were ineligible to receive surgery or combination therapy
with radiation and chemotherapy.
Advexin was delivered via injection into the tumor. Three months after
treatment, biopsies showed no viable tumor cells in 63% of patients.
Radiographic assessment of the primary tumor likewise showed that 63% of
patients had a major response. The study was conducted at M.D. Anderson
Cancer Center with Stephen Swisher, MD, as principal investigator.